211 related articles for article (PubMed ID: 20817922)
1. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
[TBL] [Abstract][Full Text] [Related]
2. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
[TBL] [Abstract][Full Text] [Related]
3. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
4. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
5. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.
Nouhin J; Donchai T; Hoang KT; Ken S; Kamkorn J; Tran T; Ayouba A; Peeters M; Chaix ML; Lien TX; Nerrienet E; Ngo-Giang-Huong N
Infect Genet Evol; 2011 Jan; 11(1):38-43. PubMed ID: 21094281
[TBL] [Abstract][Full Text] [Related]
6. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
7. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
Charpentier C; Laureillard D; Piketty C; Tisserand P; Batisse D; Karmochkine M; Si-Mohamed A; Weiss L
AIDS; 2010 Mar; 24(6):867-73. PubMed ID: 20160635
[TBL] [Abstract][Full Text] [Related]
8. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
9. Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon.
Turriziani O; Montagna C; Falasca F; Bucci M; Russo G; Lichtner M; Sobze MS; Vullo V; Pistello M; Antonelli G
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1729-33. PubMed ID: 22214532
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
11. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
12. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
15. Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil.
Arruda LB; Fonseca LA; Duarte AJ; Casseb J
AIDS Res Hum Retroviruses; 2010 Jan; 26(1):105-7. PubMed ID: 20055590
[TBL] [Abstract][Full Text] [Related]
16. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
Reigadas S; Marcelin AG; Houssaïni A; Yerly S; Descamps D; Plantier JC; Ruffault A; Amiel C; Trabaud MA; Flandre P; Fleury H; Masquelier B;
J Antimicrob Chemother; 2013 Apr; 68(4):969-72. PubMed ID: 23184711
[No Abstract] [Full Text] [Related]
18. Detection of drug resistance-associated mutations in human immunodeficiency virus type 1 integrase derived from drug-naive individuals in Surabaya, Indonesia.
Kotaki T; Khairunisa SQ; Sukartiningrum SD; Witaningrum AM; Rusli M; Diansyah MN; Arfijanto MV; Rahayu RP; Nasronudin ; Kameoka M
AIDS Res Hum Retroviruses; 2014 May; 30(5):489-92. PubMed ID: 24328535
[TBL] [Abstract][Full Text] [Related]
19. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.
Malet I; Soulie C; Tchertanov L; Derache A; Amellal B; Traore O; Simon A; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Med Virol; 2008 May; 80(5):754-61. PubMed ID: 18360887
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
